Combining cabozantinib, nivolumab and ipilimumab in advanced hepatocellular carcinoma: does benefit outweigh toxicity?

Chin Clin Oncol. 2024 Jan 19:cco-23-106. doi: 10.21037/cco-23-106. Online ahead of print.

Authors

Thiago A Miranda¹, Daniel M Girardi¹, Allan A L Pereira²

Affiliations

¹ Department of Medical Oncology, Hospital Sírio-Libanês, Brasília, Brazil.
² Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.

PMID: 38247721
DOI: 10.21037/cco-23-106

No abstract available

Keywords: Hepatocellular carcinoma (HCC); cabozantinib; immunotherapy; ipilimumab; nivolumab.